Floatz logo

Linerixibat

Pruritus

GlaxoSmithKlineSmall moleculePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Pruritus cohort.

Asset / SponsorPhaseRating
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Rabin Medical Center
Phase 4BB
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3B
Sertraline
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2B
ep547
Escient Pharmaceuticals, Inc
Phase 2B
Nalmefene
Tharimmune Inc
Phase 2CCC
Capsaicin
Aalborg University
N/AD
L-Menthol
Aalborg University
N/AD
Trans-Cinnamaldehyde
Aalborg University
N/AD

Same molecule, other indications

Linerixibat is also rated in:

cholestasisDormant
BB
Indicative ·
70 / 100
View asset →
intrahepatic cholestasisDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →